» Articles » PMID: 20966918

Linking Alzheimer's Disease to Insulin Resistance: the FoxO Response to Oxidative Stress

Overview
Journal Mol Psychiatry
Date 2010 Oct 23
PMID 20966918
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress is an important determinant not only in the pathogenesis of Alzheimer's disease (AD), but also in insulin resistance (InsRes) and diabetic complications. Forkhead box class O (FoxO) transcription factors are involved in both insulin action and the cellular response to oxidative stress, thereby providing a potential integrative link between AD and InsRes. For example, the expression of intra- and extracellular antioxidant enzymes, such as manganese-superoxide dismutase and selenoprotein P, is regulated by FoxO proteins, as is the expression of important hepatic enzymes of gluconeogenesis. Here, we review the molecular mechanisms involved in the pathogenesis of AD and InsRes and discuss the function of FoxO proteins in these processes. Both InsRes and oxidative stress may promote the transcriptional activity of FoxO proteins, resulting in hyperglycaemia and a further increased production of reactive oxygen species (ROS). The consecutive activation of c-Jun N-terminal kinases and inhibition of Wingless (Wnt) signalling may result in the formation of β-amyloid plaques and τ protein phosphorylation. Wnt inhibition may also result in a sustained activation of FoxO proteins with induction of apoptosis and neuronal loss, thereby completing a vicious circle from oxidative stress, InsRes and hyperglycaemia back to the formation of ROS and consecutive neurodegeneration. In view of their central function in this model, FoxO proteins may provide a potential molecular target for the treatment of both InsRes and AD.

Citing Articles

Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies.

Meng X, Zhang H, Zhao Z, Li S, Zhang X, Guo R Mol Med. 2025; 31(1):61.

PMID: 39966707 PMC: 11834690. DOI: 10.1186/s10020-025-01101-z.


DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer's disease.

Li V, Han Y, Kaistha T, Zhang Q, Downey J, Gozes I Sci Rep. 2025; 15(1):2093.

PMID: 39814937 PMC: 11735786. DOI: 10.1038/s41598-025-85947-7.


Inhibition of zDHHC7-driven protein S-palmitoylation prevents cognitive deficits in an experimental model of Alzheimer's disease.

Natale F, Spinelli M, Rinaudo M, Gulisano W, Nifo Sarrapochiello I, Aceto G Proc Natl Acad Sci U S A. 2024; 121(49):e2402604121.

PMID: 39589870 PMC: 11626176. DOI: 10.1073/pnas.2402604121.


Exploring Therapeutic Strategies: The Relationship between Metabolic Disorders and FOXO Signalling in Alzheimer's Disease.

Kaur P, Khan H, Grewal A, Dua K, Singh S, Gupta G CNS Neurol Disord Drug Targets. 2024; 24(3):196-207.

PMID: 39473249 DOI: 10.2174/0118715273321002240919102841.


The Influence of Circadian Rhythms on DNA Damage Repair in Skin Photoaging.

Su Z, Hu Q, Li X, Wang Z, Xie Y Int J Mol Sci. 2024; 25(20).

PMID: 39456709 PMC: 11507642. DOI: 10.3390/ijms252010926.